TAGAMET
Pronunciation: sye-MET-i-deen


What it isH2 receptor antagonist suppressing gastric acid; GERD and ulcer disease.
Why this oneIts antiandrogen action can cause gynecomastia, a peculiar liability not shared by famotidine.
What limits itInhibits multiple CYP enzymes and tubular creatinine secretion, creating interactions and a false creatinine rise; famotidine has replaced it.
Animated chart of estimated U.S. prescriptions per year, Acid-suppressing meds (1977–2026). Cimetidine enters in 1977 (estimated).
Principal riskInhibits four CYP enzymes; famotidine has replaced it
Legacy pregnancy categoryB
Defining liabilityLong-term infection, magnesium/B12 and bone risks; selected agents have clinically important CYP interactions.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Heartburn relief (OTC) | Adults & children ≥12 yr | 200 mg (1 tablet) with water PRN | 200 mg PRN | 2 tablets/24h |
| Heartburn prevention (OTC) | Adults & children ≥12 yr | 200 mg (1 tablet) up to 30 min before trigger food/drink | 200 mg PRN | 2 tablets/24h |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Undefined
Lactation Undefined
Generic entry1994
Open Cimetidine in the interactive console ↗




Open Cimetidine in the interactive console ↗